These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 838805)

  • 1. A simple thin-layer chromatographic identification procedure for erythromycin base, stearate, estolate and ethylsuccinate.
    Vilim A; LeBelle MJ; Wilson WL; Graham KC
    J Chromatogr; 1977 Mar; 133(1):239-44. PubMed ID: 838805
    [No Abstract]   [Full Text] [Related]  

  • 2. Erythromycin in the aqueous. Comparative concentrations form the estolate and from the base.
    Nolan J; Lyle WH
    Trans Ophthalmol Soc U K (1962); 1976 Jul; 96(2):338-40. PubMed ID: 797069
    [No Abstract]   [Full Text] [Related]  

  • 3. High-performance liquid chromatographic assay of erythromycin and its esters using electrochemical detection.
    Croteau D; Vallée F; Bergeron MG; LeBel M
    J Chromatogr; 1987 Aug; 419():205-12. PubMed ID: 3499443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythromycin series. IV. Thin-layer chromatography of erythromycin, erythromycin oxime, erythromyclamine and their acyl derivatives.
    Kobrehel G; Tamburasev Z; Djokić S
    J Chromatogr; 1977 Mar; 133(2):415-9. PubMed ID: 838822
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetic advantages of erythromycin estolate over ethylsuccinate as determined by high-pressure liquid chromatography.
    Croteau D; Bergeron MG; LeBel M
    Antimicrob Agents Chemother; 1988 Apr; 32(4):561-5. PubMed ID: 3259856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate.
    Keeffe EB; Reis TC; Berland JE
    Dig Dis Sci; 1982 Aug; 27(8):701-4. PubMed ID: 6980110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of erythromycin ethylsuccinate and estolate in infants under 4 months of age.
    Patamasucon P; Kaojarern S; Kusmiesz H; Nelson JD
    Antimicrob Agents Chemother; 1981 May; 19(5):736-9. PubMed ID: 6975059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythromycin therapy for group A streptococcal pharyngitis. Results of a comparative study of the estolate and ethylsuccinate formulations.
    Ginsburg CM; McCracken GH; Crow SD; Dildy BR; Morchower G; Steinberg JB; Lancaster K
    Am J Dis Child; 1984 Jun; 138(6):536-9. PubMed ID: 6372437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma bactericidal activity after administration of erythromycin estolate and erythromycin ethylsuccinate to healthy volunteers.
    Bérubé D; Kirouac D; Croteau D; Bergeron MG; Lebel M
    Antimicrob Agents Chemother; 1988 Aug; 32(8):1227-30. PubMed ID: 3142349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.
    Welling PG; Elliott RL; Pitterle ME; Corrick-West HP; Lyons LL
    J Pharm Sci; 1979 Feb; 68(2):150-5. PubMed ID: 423080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of an oral erythromycin product.
    Fraser DG
    Am J Hosp Pharm; 1980 Sep; 37(9):1199-205. PubMed ID: 6998290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythromycin estolate impairs the mitochondrial and microsomal calcium homeostasis: correlation with hepatotoxicity.
    Richelmi P; Baldi C; Manzo L; Berte F; Martino AP; Mirabelli F; Bellomo G
    Arch Toxicol Suppl; 1984; 7():298-302. PubMed ID: 6595996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythromycin jaundice: diagnosis by an in vitro challenge test.
    Cooksley WG; Powell LW
    Aust N Z J Med; 1977 Jun; 7(3):291-3. PubMed ID: 269690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of group A streptococcal pharyngitis: a randomized controlled study of twice-daily erythromycin ethylsuccinate versus erythromycin estolate.
    Ginsburg CM; McCracken GH; Steinberg JB; Crow SD; Dildy BF; Lancaster K; Olsen K
    Pediatr Infect Dis; 1982; 1(6):384-7. PubMed ID: 6761656
    [No Abstract]   [Full Text] [Related]  

  • 15. Bioautography of erythromycin and its esters.
    Easterbrook SM; Hersey JA
    J Chromatogr; 1976 Jun; 121(2):390-4. PubMed ID: 932154
    [No Abstract]   [Full Text] [Related]  

  • 16. Concentrations of erythromycin in serum and tonsil: comparison of the estolate and ethyl succinate suspensions.
    Ginsburg CM; McCracken GH; Culbertson MC
    J Pediatr; 1976 Dec; 89(6):1011-3. PubMed ID: 792404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of the bioavailabilities of erythromycin estolate and erythromycin ethylsuccinate dry suspension preparations in steady state].
    Potthast H; Schug B; Elze M; Schwerdtle R; Blume H
    Pharmazie; 1995 Jan; 50(1):56-60. PubMed ID: 7886126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simple thin-layer chromatographic identification method for erythromycin stearate.
    Graham KC; Wilson WL; Vilim A
    J Chromatogr; 1976 Oct; 125(2):447-50. PubMed ID: 977688
    [No Abstract]   [Full Text] [Related]  

  • 19. Erythromycin estolate and jaundice.
    Inman WH; Rawson NS
    Br Med J (Clin Res Ed); 1983 Jun; 286(6382):1954-5. PubMed ID: 6407653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative bioavailability evaluation of erythromycin base and its salts and esters. I. Erythromycin estolate capsules versus enteric-coated erythromycin base tablets.
    DiSanto AR; Tserng KY; Chodos DJ; DeSante KA; Albert KS; Wagner JG
    J Clin Pharmacol; 1980 Jul; 20(7):437-43. PubMed ID: 7430412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.